Cargando…

Implementation & yield of upfront genomic profiling in a clinical prostate cancer diagnostic pathway

Detalles Bibliográficos
Autores principales:	Massie, Charlie, Gnanapragasam, Vincent, Barrett, Tristan, Warren, Anne, Anand, Shubha, Keates, Alexandra, Pacey, Simon
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7615268/ https://www.ncbi.nlm.nih.gov/pubmed/37431085 http://dx.doi.org/10.1111/bju.16101

Ejemplares similares

Prospective Implementation and Early Outcomes of a Risk-stratified Prostate Cancer Active Surveillance Follow-up Protocol
por: Thankapannair, Vineetha, et al.
Publicado: (2023)

A Feasibility Study of the Therapeutic Response and Durability of Short-term Androgen-targeted Therapy in Early Prostate Cancer Managed with Surveillance: The Therapeutics in Active Prostate Surveillance (TAPS01) Study
por: Barrett, Tristan, et al.
Publicado: (2022)

Multi-transcript profiling in archival diagnostic prostate cancer needle biopsies to evaluate biomarkers in non-surgically treated men
por: Kachroo, Naveen, et al.
Publicado: (2014)

Assessing the impact of MRI based diagnostics on pre-treatment disease classification and prognostic model performance in men diagnosed with new prostate cancer from an unscreened population
por: Lophatananon, Artitaya, et al.
Publicado: (2022)

Development and External Validation of the STRATified CANcer Surveillance (STRATCANS) Multivariable Model for Predicting Progression in Men with Newly Diagnosed Prostate Cancer Starting Active Surveillance
por: Light, Alexander, et al.
Publicado: (2022)

Evaluation of transabdominal and transperineal ultrasound-derived prostate specific antigen (PSA) density and clinical utility compared to MRI prostate volumes: A feasibility study
por: Pantelidou, Maria, et al.
Publicado: (2022)

Resolving the immune landscape of human prostate at a single-cell level in health and cancer
por: Tuong, Zewen Kelvin, et al.
Publicado: (2021)

MRI-derived radiomics model for baseline prediction of prostate cancer progression on active surveillance
por: Sushentsev, Nikita, et al.
Publicado: (2021)

Diagnostic evaluation of magnetization transfer and diffusion kurtosis imaging for prostate cancer detection in a re-biopsy population
por: Barrett, Tristan, et al.
Publicado: (2017)

Time series radiomics for the prediction of prostate cancer progression in patients on active surveillance
por: Sushentsev, Nikita, et al.
Publicado: (2023)

Comparison of initial and tertiary centre second opinion reads of multiparametric magnetic resonance imaging of the prostate prior to repeat biopsy
por: Hansen, Nienke L., et al.
Publicado: (2016)

Serial changes in tumour measurements and apparent diffusion coefficients in prostate cancer patients on active surveillance with and without histopathological progression
por: Sushentsev, Nikita, et al.
Publicado: (2022)

MRI-derived PRECISE scores for predicting pathologically-confirmed radiological progression in prostate cancer patients on active surveillance
por: Caglic, Iztok, et al.
Publicado: (2020)

Targeted transperineal biopsy of the prostate has limited additional benefit over background cores for larger MRI-identified tumors
por: Barrett, Tristan, et al.
Publicado: (2015)

Real-world evaluation of upfront docetaxel in metastatic castration-sensitive prostate cancer
por: Isaksson, Jenny, et al.
Publicado: (2021)

Comparative performance of MRI-derived PRECISE scores and delta-radiomics models for the prediction of prostate cancer progression in patients on active surveillance
por: Sushentsev, Nikita, et al.
Publicado: (2021)

Incorporating multiparametric MRI staging and the new histological Grade Group system improves risk-stratified detection of bone metastasis in prostate cancer
por: Thurtle, David, et al.
Publicado: (2016)

The effect of gadolinium-based contrast agent administration on magnetic resonance fingerprinting-based T(1) relaxometry in patients with prostate cancer
por: Sushentsev, Nikita, et al.
Publicado: (2020)

Evaluating Prostate Cancer Using Fractional Tissue Composition of Radical Prostatectomy Specimens and Pre-Operative Diffusional Kurtosis Magnetic Resonance Imaging
por: Lawrence, Edward M., et al.
Publicado: (2016)

Removing rician bias in diffusional kurtosis of the prostate using real‐data reconstruction
por: Goodburn, Rosie J., et al.
Publicado: (2019)

DEBATE UPFRONT vs DELAYED TRANSPLANT
por: Gay, F.
Publicado: (2023)

Trends in prostatectomy utilization: Increasing upfront prostatectomy and postprostatectomy radiotherapy for high‐risk prostate cancer
por: Kaps, Bryan, et al.
Publicado: (2020)

Doctors’ perceptions of the impact of upfront point-of-care testing in the emergency department
por: Goldstein, Lara Nicole, et al.
Publicado: (2018)

Discovery of PTN as a serum-based biomarker of pro-metastatic prostate cancer
por: Liu, Shiqin, et al.
Publicado: (2020)

Extensive upfront validation and testing are needed prior to the clinical implementation of AI‐based auto‐segmentation tools
por: Roper, Justin, et al.
Publicado: (2022)

Novel concepts for risk stratification in prostate cancer
por: Patel, Keval M, et al.
Publicado: (2016)

Long‐term disease control after upfront chemotherapy and surgery in a patient with primary prostate leiomyosarcoma
por: Kawaguchi, Toshiaki, et al.
Publicado: (2021)

Systemic treatment of metastatic hormone-sensitive prostate cancer—upfront triplet versus doublet combination therapy
por: Oing, C., et al.
Publicado: (2023)

Upfront Daratumumab With Lenalidomide and Dexamethasone for POEMS Syndrome
por: Gavriatopoulou, Maria, et al.
Publicado: (2020)

Surgery for Crohn’s disease: upfront or last resort?
por: Ahmed Ali, U, et al.
Publicado: (2022)

Evidence for downregulation of the negative regulator SPRED2 in clinical prostate cancer
por: Kachroo, N, et al.
Publicado: (2013)

Short-term Outcomes After Upfront Chemotherapy Followed by Curative Surgery in Metastatic Colon Cancer: A Comparison With Upfront Surgery Patients
por: Han, Myung Hyun, et al.
Publicado: (2019)

The Prostate Health Index adds predictive value to multi-parametric MRI in detecting significant prostate cancers in a repeat biopsy population
por: Gnanapragasam, V. J., et al.
Publicado: (2016)

Upfront Stereotactic Radiosurgery for Pineal Parenchymal Tumors in Adults
por: Park, Jong Hoon, et al.
Publicado: (2015)

AL AMYLOIDOSIS UPFRONT TREATMENT AND CURRENT AND FUTURE STUDIES
por: Kastritis, E.
Publicado: (2023)

Multicentre clinical evaluation of the safety and performance of a simple transperineal access system for prostate biopsies for suspected prostate cancer: The CAMbridge PROstate Biopsy DevicE (CamPROBE) study
por: Gnanapragasam, Vincent J, et al.
Publicado: (2020)

Composite risk stratification models optimise the value of imaging in prostate cancer staging
por: McAllister, Tom, et al.
Publicado: (2023)

A case of abiraterone acetate withdrawal syndrome after initiation of upfront abiraterone therapy for high‐risk prostate cancer
por: Tani, Masaru, et al.
Publicado: (2023)

Loss of hSef promotes metastasis through upregulation of EMT in prostate cancer
por: Hori, Satoshi, et al.
Publicado: (2017)

Diagnostic accuracy of urinary prostate protein glycosylation profiling in prostatitis diagnosis
por: Vermassen, Tijl, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_3jv7je405fanpehm3lir50717p